Latest Regulatory Incentives News

PYC Therapeutics has gained Orphan Drug Designation from the European Medicines Agency for its VP-001 candidate targeting Retinitis Pigmentosa type 11, enhancing its regulatory and commercial pathway in Europe.

Island Pharmaceuticals has cleared a major regulatory hurdle with the US FDA, confirming a clinical development path for its antiviral Galidesivir under the Animal Rule. Backed by a $9 million capital raise and strategic partnerships, the company is poised for potential US government procurement and biodefence market entry.

Neuren Pharmaceuticals reported a solid A$30.4 million net profit in 2025, powered by a 15% rise in DAYBUE® royalties. The company is progressing its NNZ-2591 Phase 3 trial for Phelan-McDermid syndrome and has initiated a share buy-back amid perceived undervaluation.

Vulcan Energy has officially started full-scale construction of its Lionheart lithium chemicals facility in Frankfurt, targeting a 2028 commercial production start with a capacity to supply 500,000 EV batteries annually.

First Graphene has demonstrated a significant carbon reduction in cement roof tiles through a UK production trial with FP McCann, using graphene-enhanced cement to lower emissions and material use.

Immutep Limited has won FDA Orphan Drug Designation for its immunotherapy eftilagimod alfa in treating soft tissue sarcoma, opening regulatory incentives and potential market exclusivity. This follows encouraging Phase II data despite recent Phase III trial setbacks.

Osmond Resources has made significant progress on its Orión EU Critical Minerals Project in Spain, focusing on low capital expenditure concentrate production and expanding its drilling program to support rare earth and critical mineral extraction.

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

Neuren Pharmaceuticals has initiated a discretionary on-market share buy-back program of up to 5%, citing a strong cash position and undervaluation relative to internal and analyst assessments.

Janus Electric has landed further orders worth approximately A$1.6 million from its authorised California dealer, Electric Vehicle Choice, marking a significant step in its U.S. market expansion. The orders include conversion modules, batteries, and charging infrastructure, with shipment planned for mid-2026.

Neuren Pharmaceuticals has received detailed feedback from the US FDA on its clinical development plans for NNZ-2591 targeting hypoxic ischemic encephalopathy and Pitt Hopkins syndrome, paving a clearer path forward despite some delays.

Island Pharmaceuticals has raised $9 million to advance its antiviral drug Galidesivir through the FDA’s Animal Rule pathway, targeting inclusion in the US Strategic National Stockpile for biodefense viruses.